Trinity Biotech’s OTC HIV tests?
This article was originally published in The Tan Sheet
Executive Summary
Inverness Medical Innovations grants Trinity Biotech a royalty bearing license to its lateral flow patents for all diagnostic uses except women's health and cardiology, including an OTC license for Trinity's Unigold HIV products, Trinity announces Aug. 8. Procter & Gamble signed a "non-binding letter of intent" with Inverness to develop and market consumer diagnostic products in July 1("The Tan Sheet" July 24, 2006, In Brief)...
You may also be interested in...
Inverness and P&G
Procter & Gamble has signed a "non-binding letter of intent" with Inverness Medical Innovations to "form a joint venture to develop and market consumer diagnostic products," the firms announce July 18. The planning required to reach a final agreement will "take several months," they add. The agreement will combine Inverness' experience developing and manufacturing consumer diagnostics with P&G's knowledge of marketing consumer healthcare products, Waltham, Mass.-based Inverness states. Current consumer diagnostic offerings by Inverness include several pregnancy, ovulation and fertility tests under the Clearblue, FactPlus, Accu-Clear, Persona and Clearplan brands...
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.